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packets). The most widely kept medicines are medicines for the central nervous system 
(21%), the disorders in the digestive system and metabolism (16.7%) and medicines 
for the diseases of the respiratory system (14.5%). Nearly three-fourths of opened 
packets were not entirely consumed. a large number of medicines in home pharmacies 
(79%) was obtained self initiatedly and many of them were beyond their expiry date 
(9.5%). a total of 25% of the ﬁ nancial means for those medicines was provided from 
health insurance funds. The total cost of medicines in home pharmacies per a family 
in Serbia was c25.13. a total of 72% of that amount was paid by the patients 
themselves. Pharmacoeconomic indicators in certain groups of medicines show that 
the largest percentage of the ﬁ nancial means for home pharmacies in Serbia is spent 
on the medicines for gastrointestinal problems and metabolism disorders (17%). 
CONCLUSIONS: Based on the analyzed data, self-medication, that is, unreasonable 
use of medicines, is a big problem in Serbia. The use of these medicines involves the 
risk of inadequate treatment of the illness, frequent occurrence of side-effects which 
sometimes requires additional treatment, which only increases the expenses for both 
the patients and health funds. Therefore, it is necessary to closely monitor the issuing 
of prescriptions as well as educate the population.
PHP74
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OBJECTIVES: To examine the evolution of the rate of admissions for ambulatory 
care sensitive conditions in beneﬁ ciaries of a health care plan, monitoring of access to 
the health system and its performance and identifying strategies that will enable the 
improvement of the health situation of the population and the appropriate allocation 
of resources. METHODS: Retrospective analysis of 212,360 hospital admissions, 
occurring between 1999 and 2008, among beneﬁ ciaries of a health care plan, resident 
in Brazil. The outcome of the study was the proportion of admissions for primary 
care sensitive conditions, identiﬁ ed by ICD-10. The proportion of these admissions in 
relation to the total hospital admissions was established, as well as the quotient for 
the number of hospital admissions and the population, either total or by age group 
and speciﬁ c causes, besides hospital direct costs. The signiﬁ cance was tested and 
estimates of the rates were deﬁ ned based on their 95% conﬁ dence intervals. RESULTS: 
Admissions for primary care sensitive conditions accounted for 55,307 of 212,360 
admissions reimbursed by the health plan (26.0%). The rate of admission for primary 
care sensitive conditions fell by 28.0% during the period (from 347.6 to 250.3 per 10 
thousand). The most frequent cause was gastroenteritis (30.9%), followed by arterial 
hypertension (13.6%), cerebrovascular diseases (9.6%), heart failure (8.1%), kidney 
and urinary tract infections (6.8%), diabetes mellitus (5.8%) and angina pectoris 
(5.5%). The mean annual expenditure on admissions was R$15,232,494 against 
R$51,440,680 for other conditions (22.8%). CONCLUSIONS: The reduction 
observed in the rate of admissions for primary care sensitive conditions suggests pos-
sible improvements in primary health care. Further actions and strategies could reduce 
the number of avoidable admissions and contribute to the ﬁ nancial balance of the 
health care plan.
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OBJECTIVES: The purpose of this longitudinal descriptive study was to evaluate the 
inﬂ uence of interventions by clinical pharmacists on processes, outcomes of care and 
economical outcomes. METHODS: The patients who were hospitalized at internal 
medicine wards, Songkhla hospital during October 1, 2008-September 30, 2009 were 
recruited to this study. The core set of clinical pharmacy services were admission drug 
histories, drug protocol management, adverse drug reaction management, drug infor-
mation, medical rounds and patient discharge counseling. The clinical pharmacists 
collected patients’ data, pharmacists’ interventions, direct drug cost-saving and activi-
ties on a speciﬁ c designated form. The data was processed on a computerized database. 
Clinical pharmacist interventions were counted and classiﬁ ed and analyzed to deter-
mine the inﬂ uence on the quality and cost of pharmacotherapy. Descriptive statistics 
were used in data analysis. RESULTS: At the end of the study period the following 
were found: a total of 3796 patients were recruited. Clinical pharmacy services on 
internal medicine wards contribute to maximizing the pharmacotherapeutic effect and 
rationalization of drug therapy in 609 patients (16.0%), increase medication safety in 
338 patients (8.9%) and reducing drug expenditures in 575 patients (15.1%). Cost-
saving from reconciling process was US$12,682 and cost-saving from pharmacists’ 
interventions were US$6,298. The frequent type of interventions was maximizing the 
pharmacotherapeutic effect (40.8%), rationalization of drug therapy (30.3%) and 
minimizing the risk for developing adverse drug effects (28.9%), respectively. The top 
two of drug related problems found in cardiovascular drugs (30.5%) and antibiotic 
drugs (24.8%), respectively. CONCLUSIONS: The results of this study indicate that 
inpatient clinical pharmacy services on internal medicine wards contribute to ratio-
nalization of drug therapy, increase medication safety and reduced the direct expen-
ditures on medications. Therefore, future studies should include multiple sites such as 
in a general surgical department and clinical pharmacy services should be 
continued.
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OBJECTIVES: Funding for health care programs competes with funding for professional 
education (ie, implementation of health care programs) and funding for research to 
reduce uncertainty around program cost-effectiveness. No study has yet shown how to 
allocate a combined budget for health care, professional education, and research. Previ-
ous work did not consider the fundamental idea that interventions with an acceptable 
incremental cost-effectiveness ratio (ICER) for an adoption decision may not be accept-
able any more once implementation decisions are made simultaneously. Furthermore, 
previous work did not consider that cost-effectiveness of research is conditional upon 
the programs chosen for adoption and implementation. The purpose of this work is to 
present a sequential process to allocate a combined budget with the goal to maximize 
health. METHODS: Development of a 3-step allocation process to maximize health 
based on a single budget for health care, professional education, and research RESULTS: 
As a ﬁ rst step, a league table approach determines which programs would be funded if 
the combined budget were spent just on adoption. The second step analytically deter-
mines a new (lower) threshold ICER which maximizes health by discontinuing programs 
above the new threshold and investing in implementing programs below the threshold. 
The third step considers cost-effectiveness of research to reduce uncertainty around 
program cost-effectiveness. In order to fund this research, the threshold ICER for adop-
tion plus implementation has to be reduced further. In order to maximize health, ICERs 
of research studies need to equal the newly deﬁ ned threshold ICER for adoption plus 
implementation. CONCLUSIONS: A 3-step allocation process is able to maximize 
health based on a single budget for health care, professional education, and research. 
Compared to a programming approach the proposed approach yields a closed-form 
analytical solution and is able to consider that research decisions are conditional upon 
adoption and implementation choices.
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OBJECTIVES: To investigate the motives of both contracting parties, sick funds and 
pharmaceutical companies, to enter into direct contracts on patent-protected pharma-
ceuticals in the outpatient sector in Germany. METHODS: A systematic literature 
review was performed in March 2010 to identify contracts on patent-protected phar-
maceuticals in Germany. Standard literature databases such as Pubmed and EMBASE, 
different market research databases and the ‘Lauer-Taxe’, the ofﬁ cial German price 
registry for pharmaceuticals were utilised. We included only ofﬁ cially reported contracts. 
a detailed market analysis was conducted to identify the motives of the identiﬁ ed con-
tracts. RESULTS: The number of direct contracts has been recently increasing. a total 
of 116 contracts were found. Formally, they are all rebate contracts due to German law. 
However, they include risk-sharing (n = 6), cost-sharing (2), added value (5) and simple 
rebate contracts (103). For sick funds, major motives were cost cutting, positioning 
within the market, attracting the “right” members, improving the medical treatment 
and right coding. Pharmaceutical companies show several motives that can be clustered 
into proactive and reactive motives: Proactive motives were: gaining access to reimburse-
ment beyond standard coverage, funding of managed care concepts, bridging a time gap 
until market entry of a successor, maintaining the attractiveness after patent expiration 
as well as shaping the market access environment. Reactive motives were: rebate con-
tracts of competitors, limitations and exclusions from reimbursement by the federal joint 
committee as well as reacting to attempts by sick funds and Associations of Statutory 
Health Insurance Physicians to control drug expenditures. CONCLUSIONS: Direct 
contracting on patent-protected pharmaceuticals seems to play a increasing role in the 
strategic considerations of pharmaceutical companies and sick funds.
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OBJECTIVES: Requirements for a Health Technology Assessment (HTA) submission vary 
within the UK (England and Wales [National Institute for Health and Clinical Excellence 
(NICE)], Scotland [Scottish Medicines Consortium (SMC)], and Wales [All Wales Medi-
cines Strategy Group (AWMSG)]) and the Republic of Ireland (National Centre for 
Pharmacoeconomics [NCPE]). The objective of this study is to determine whether the 
likelihood of reimbursement in these markets is linked to HTA submission requirements. 
METHODS: Dossier requirements issued by NCPE, NICE, SMC and AWMSG were 
compared, and a checklist of requirements compiled. We investigated 20 interventions 
most recently reviewed by the NCPE, and recorded the recommendations for these com-
pared with those issued by NICE, SMC and AWMSG. RESULTS: Economic analysis is 
key for an NCPE submission, although there are no speciﬁ c requirements or template for 
the clinical data. Requirements for NICE are the most stringent; SMC and AWMSG have 
similar requirements. Of 20 interventions reviewed by NCPE, 11 (55%) were reimbursed 
